You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 海普瑞(9989.HK)反彈近6% 國內在售五個規格依諾肝素鈉注射液通過一致性評價
格隆匯 10-29 15:19
格隆匯10月29日丨近期弱勢的海普瑞(9989.HK)今日創新低後反彈上漲,現報13.08港元,漲5.65%,總市值331億港元。海普瑞日前公告,全資附屬深圳天道於中國在售之全部五個規格的依諾肝素鈉注射液通過仿製藥品質和療效一致性評價。目前相關產品已合共在35個國家獲批,並在21個國家實現銷售。在今年上半年,公司依諾製劑全球銷售額按年增長37%至6.4億元人民幣。業內人士指出,通過一致性評價後,有利於天道醫藥在藥品集中採購不斷推廣的新市場環境下搶佔先機,海普瑞在中國市場的製劑業務發展將迎來重大機遇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account